RedHill Biopharma Ltd. (NasdaqCM: RDHL)
Health Care · Pharmaceuticals · IL
$0.54
+7.80% today · -66.9% 1Y
RedHill Biopharma Ltd. (NasdaqCM: RDHL) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.28M and employs 13 people.
Over the last twelve months the share price has lost 66.9%, trading between 0.44 and 2.14.
Tweenvest scores RedHill Biopharma Ltd. across four factors: quality 23/100, value 46/100, growth 0/100. Its strongest factor is value.
RDHL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.28M
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- 4.90
- 52-week high
- $2.14
- 52-week low
- $0.44
- Avg volume (3M)
- —
- Shares outstanding
- 6.08M
- Employees
- 13
- Next earnings
- —
About RedHill Biopharma Ltd.
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
- ISIN
- US7574683014
- Founded
- 2009
- Listed since
- Jan 7, 2013
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| 60 Degrees Pharmaceuticals, Inc.NasdaqCM: SXTP | $3.40M | $0.97 | -30.55% |
| CTT Pharmaceutical Holdings, Inc.OTCPK: CTTH | $3.38M | $0.06 | +2.91% |
| ODI Pharma AB (publ)NGM: ODI | $3.32M | Skr1.81 | -7.18% |
| Sanai Health Industry Group Company LimitedSEHK: 1889 | $3.31M | HK$0.17 | -10.99% |
| Cadrenal Therapeutics, Inc.NasdaqCM: CVKD | $3.25M | $0.91 | -2.10% |
| Goldline Pharmaceutical LimitedBSE: 544759 | $3.22M | Rs32.50 | +4.94% |
| Herbal Dispatch Inc.CNSX: HERB | $3.21M | CA$0.04 | +16.67% |
| PRF Technologies Ltd.NasdaqCM: PRFX | $3.08M | $0.88 | -4.47% |
Figures last refreshed Oct 11, 2026.